Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Susan Dos Reis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Dementia, Herpes Zoster Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, GlaxoSmithKline.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Herpes zoster vaccines may lower the risk of dementia onset. We evaluated new‐onset dementia among US Medicare beneficiaries ≥65 years old following recombinant zoster vaccination (RZV). METHODS We matched one RZV‐exposed to two RZV‐unvaccinated on age, sex, and race/ethnicity. Individuals were ≥65 years old on the RZV dose 2 date (RZV‐exposed) or preventive care visit date (RZV‐unvaccinated), enrolled in Medicare ≥11 months before this date, and had no pre‐existing dementia of any type. Weighted Cox proportional hazards models generated hazard ratios (HR) of new‐onset dementia, Alzheimer's disease (AD), and vascular dementia (VD). RESULTS The incidence per 1000 person‐years of new‐onset dementia for 15,061/502,845 RZV‐exposed and 36,526/1,005,690 RZV‐unvaccinated was 10.45 and 15.73, respectively. Time‐dependent HRs (95% confidence interval) for ≤3 and >3 years’ follow‐up were as follows: 0.67 (0.65, 0.68); 0.74 (0.69, 0.79) for dementia; 0.72 (0.69, 0.74); 0.83 (0.74, 0.94) for AD; 0.67 (0.64, 0.70); 0.66 (0.57, 0.78) for VD. DISCUSSION Two‐dose RZV may lower new‐onset dementia, AD, and VD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
- Global Vaccine and Infectious Disease Epidemiology, GSK, Rockville, Maryland, USA.
ORCID-Profile: Susan Dos Reis
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Dos Reis, S., Tran, P., Mohanty, K., Amill-Rosario, A., Johnson, A., Ryan, K., Alsdurf, H., Oraichi, D., & Yun, H. (2026). Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71407
Vancouver
Dos Reis S, Tran P, Mohanty K, Amill-Rosario A, Johnson A, Ryan K, et al. Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71407
BibTeX
@article{DosReis2026,
author = {Dos Reis, Susan and Tran, Phuong and Mohanty, Kareshma and Amill-Rosario, Alejandro and Johnson, Abree and Ryan, Kathleen and Alsdurf, Hannah and Oraichi, Driss and Yun, Huifeng},
title = {Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71407}
}
EUVIMED